Ignite Creation Date:
2025-12-24 @ 12:03 PM
Ignite Modification Date:
2025-12-30 @ 2:56 AM
Study NCT ID:
NCT01583361
Status:
UNKNOWN
Last Update Posted:
2012-04-24
First Post:
2012-04-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer
Sponsor:
Lin Chen
Organization:
Study Overview
Official Title:
Phase III, Randomized, Multicenter, Controlled Evaluation of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Advanced Gastric Cancer Patients
Status:
UNKNOWN
Status Verified Date:
2012-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RESONANCE
Brief Summary:
This is a randomized, multicenter, controlled trial to prove efficacy of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Advanced Gastric Cancer Patients who undergo D2 gastrectomy.
The primary endpoint is three-year free disease and the second primary includes five-year overall survival, safety and R0 resection rate.
The primary endpoint is three-year free disease and the second primary includes five-year overall survival, safety and R0 resection rate.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: